Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hartmann R et al. – This indicates that the introduced mutations not only affected the activity of FIXa but may have also influenced the lifetime of the activated mutant molecules in plasma by modifying their activation and/or inhibition rates.

Related Articles

X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
New England Journal of Medicine, 10/22/09    Relevance Score: 83%

Intrinsic clotting factors in dependency of age, sex, body mass index, and oral contraceptives: definition and risk of elevated clotting factor levels
Blood Coagulation & Fibrinolysis, 10/05/09    Relevance Score: 68%

c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes
Oncogene, 10/08/09    Relevance Score: 66%

Unexplained fetal loss: the fetal side of thrombophilia
Fertility and Sterility, 11/12/09    Relevance Score: 65%

Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation
Blood, 10/09/09    Relevance Score: 65%

Today in Coagulation/Bleeding Dz...keeping you current

Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies
Best Practice & Research: Clinical Haematology , 12/09/09

Developments in factor Xa inhibitors for the treatment of thromboembolic disorders
Medicinal Research Reviews, 12/09/09

Diagnosis of platelet-type von Willebrand disease by flow cytometry
Haematologica, 12/09/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address